Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Celgene: Oral OTEZLA Shows Long-Term Benefits For Active Psoriatic Arthritis

RELATED NEWS
Trade CELG now with 

Celgene International Sàrl, an unit of Celgene Corp. (CELG: Quote), reported results of additional analyses from the phase III trials of OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 or PDE4. These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1.

"People with psoriatic arthritis live with persistent symptoms of this painful disease," said Georg Schett, director of the Department of Internal Medicine III - Rheumatology and Immunology, University Hospital Erlangen, Germany. "These analyses of one-year data from the PALACE trials suggest that, based on the efficacy and safety data we've seen to-date, OTEZLA has the potential to help patients for the long-term management of manifestations of their psoriatic arthritis," he added.

The long-term (52-week) results from three trials showed that treatment with OTEZLA improved measures of psoriatic arthritis disease activity, including tender and swollen joints, compared with placebo at 16 weeks.

Long-term safety results from an analysis of pooled data from the PALACE 1, 2 and 3 trials identified no new safety findings for patients with psoriatic arthritis who were treated with OTEZLA for up to 52 weeks, compared with the previously reported 24-week safety results.

Register
To receive FREE breaking news email alerts for Celgene Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.